Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-Escalated Chemotherapy for HR+/ERBB2+
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial
JAMA Oncol 2023 May 11;[EPub Ahead of Print], O Gluz, UA Nitz, M Christgen, S Kuemmel, J Holtschmidt, J Schumacher, A Hartkopf, J Potenberg, K Lüedtke-Heckenkamp, M Just, C Schem, R von Schumann, C Kolberg-Liedtke, CZ Eulenburg, T Schinköthe, M Graeser, R Wuerstlein, RE Kates, HH Kreipe, N HarbeckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.